Among the four agents tested in our study, CMP5 exhibited consistent specificity for PRMT5, blocked cell-cycle progression in GBM neurospheres, and drove GBM neurospheres toward the senescent phenotype [75]. The gene discussed is PRMT5; the disease is glioblastoma.